Kangfang Life Sciences (09926.HK): Over 40 clinical research results of various innovative drugs will be released at ASCO in 2026.

The Zhitong Finance APP news, Kangfang Biotech (09926.HK) announced that a total of more than 40 clinical research results of multiple innovative drugs independently developed by the company will be officially released at the 2026 American Society of Clinical Oncology (ASCO). The research mainly focuses on the company's globally pioneering dual antibody core products, Kadecnil(Value 1000 Reconciliation/CTLA-4), Evieci (Value 1000/VEGF), as well as the next-generation CD47 antibody Levafli, covering areas such as non-small cell lung cancer, small cell lung cancer, colorectal cancer, renal cell carcinoma, melanoma, colon cancer, head and neck cancer, gynecologic tumors, and bile duct cancer. This fully showcases the breakthrough and extensive clinical value of the company's innovative drugs.